Study of a new pill for pulmonary hypertension
Part of Brain & nervous system, Genetic & congenital, Heart & circulation, Lungs & breathing clinical trials.
This study tests a new pill, ROC-101, for people with pulmonary hypertension (high blood pressure in the lungs). It aims to see if the pill can improve symptoms and daily function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of pulmonary hypertension (Group 1 or Group 3) from a right heart catheterization.
- You must have symptoms like shortness of breath or fatigue (WHO Functional Class II or III).
- You must be on stable medications for your condition.
- You must be able to walk between 100 and 550 meters in 6 minutes.
- You must be able to swallow tablets.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication called REGN13335 for people with pulmonary arterial hypertension (PAH). It aims to see if the drug can improve symptoms and function compared to standard care alone.
This trial tests a new drug called IMC-003 for people with pulmonary arterial hypertension (PAH). It aims to see if the drug can help improve symptoms and exercise ability when added to your current PAH medications.
This trial compares starting with two oral medications versus one for people newly diagnosed with pulmonary arterial hypertension (PAH) who also have conditions like high blood pressure, diabetes, obesity, or heart disease. The goal is to see if a two-drug approach works better for patients with these additional health issues.
This trial tests whether a new form of tacrolimus (a medication that helps calm the immune system) can improve breathing and exercise ability in people with pulmonary arterial hypertension (high blood pressure in the lungs) who are still limited despite current treatments. The study aims to see if this drug can help patients walk farther and feel less short of breath.
This study looks at how patients feel and how well they stick with their treatment when they switch from an inhaled medicine (iloprost) to a pill (selexipag) for pulmonary arterial hypertension (PAH). It will help doctors understand if the switch improves patient experience.
This trial tests a combination of three medications (an endothelin receptor antagonist, a PDE5 inhibitor, and sotatercept) as the first treatment for people newly diagnosed with pulmonary arterial hypertension (PAH). It aims to see if starting with all three together works better than the usual approach.
Hear when a new Pulmonary Arterial Hypertension (PAH) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.